Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression1

Abstract

Twenty-six patients with advanced renal cell carcinoma were treated with suramin administered by continuous infusion, with dosing deter mined by a nomogram. One patient achieved a partial response and five patients achieved a minor response or had stable disease for >3 months. Toxicities included an immune-mediated thrombocytopenia in one pa tient and… (More)

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Motzer2006PhaseIT, title={Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression1}, author={Robert John Motzer and David M. Nanus and Paul V O'Moore and Howard I. Scher and Dean F Bajorin and Victor Reuter and William Tong and Jacqueline Iversen and Carl Louison and Anthony P. Albino and George J. Bosl}, year={2006} }